Dai Shimizu

Dai Shimizu


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2015 in International Journal of Oncology
Verified
Journal Article
Open access
HTHaruyoshi Tanaka
Haruyoshi Tanaka
MKMitsuro Kanda
Mitsuro Kanda
MKMasahiko Koike
Masahiko Koike
NINaoki Iwata
Naoki Iwata
DSDai Shimizu
Dai Shimizu
YKYasuhiro Kodera
Yasuhiro Kodera
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

30 June 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
KEKazuhiro Ezaka
Kazuhiro Ezaka
MKMitsuro Kanda
Mitsuro Kanda
HSHiroyuki Sugimoto
Hiroyuki Sugimoto
DSDai Shimizu
Dai Shimizu
HOHisaharu Oya
Hisaharu Oya
YKYasuhiro Kodera
Yasuhiro Kodera

1 September 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MSMasaya Suenaga
Masaya Suenaga
Tsutomu FujiiTsutomu Fujii
Tsutomu Fujii
SYSuguru Yamada
Suguru Yamada
MHMasamichi Hayashi
Masamichi Hayashi
KSKeiko Shinjo
Keiko Shinjo
YKYasuhiro Kodera
Yasuhiro Kodera

29 October 2019 in In Vivo
Verified
Journal Article
Open access
PDF file
TMTakashi Miwa
Takashi Miwa
MKMitsuro Kanda
Mitsuro Kanda
SUShinichi Umeda
Shinichi Umeda
HTHaruyoshi Tanaka
Haruyoshi Tanaka
DSDai Shimizu
Dai Shimizu
YKYasuhiro Kodera
Yasuhiro Kodera
Background/Aim: Establishment of mouse xenograft models is necessary for oncological research and depends on the characteristics of the cell lines and the immune system of the host. In this study, we describe the development of mouse xenograft models using human gastric cancer (GC) cell lines. Materials and Methods: MKN1 stably-expressing luciferase (MKN1-Luc), N87, KATO III, MKN45 stably-expressing luciferase (MKN45-Luc), NUGC4, and OCUM-1 human GC cell lines were injected intraperitoneally into mice to establish peritoneal metastasis models. MKN45-Luc were injected into subcutaneously implanted spleen, and MKN1-Luc and MKN45-Luc were injected directly into the portal veins of mice for the establishment of hepatic metastasis models. Results: Peritoneal metastasis was formed after implantation of MKN1-Luc, N87, KATO III, MKN45-Luc, and NUGC4 in nude mice, but not formed in OCUM-1 even in NOD/SCID mice. After intrasplenic injection of MKN45-Luc, we found no hepatic metastasis formation. We identified hepatic metastasis formation after direct injection of MKN45-Luc and MKN1-Luc into the portal veins of NOD/SCID mice. Conclusion: Peritoneal and hepatic metastasis mouse xenograft models were successfully established using several human GC cell lines.

30 July 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
MKMitsuro Kanda
Mitsuro Kanda
DSDai Shimizu
Dai Shimizu
SNShunsuke Nakamura
Shunsuke Nakamura
KSKoichi Sawaki
Koichi Sawaki
SUShinichi Umeda
Shinichi Umeda
YKYasuhiro Kodera
Yasuhiro Kodera

15 June 2020 in Nutrition and Cancer
Verified
Journal Article
Closed access
MHMasamichi Hayashi
Masamichi Hayashi
SYSuguru Yamada
Suguru Yamada
HTHiroshi Tanabe
Hiroshi Tanabe
HTHideki Takami
Hideki Takami
YIYoshikuni Inokawa
Yoshikuni Inokawa
YKYasuhiro Kodera
Yasuhiro Kodera
Background: The Apolipoprotein-related MORtality RISk (AMORIS) study in Sweden revealed that serum uric acid (SUA) was significantly associated with hepatobiliary cancer occurrence. However, the association with postoperative hepatocellular carcinoma (HCC) recurrence has not been reported. Methods: A total of 256 surgically resected HCC patients were included (from January 2003 to December 2017) in this study. Comparisons in terms of clinicopathologic factors and long-term outcomes were made between patients with high SUA (>6.1 mg/dl) at the time of hepatectomy and low SUA. Besides, SUA data at one postoperative year (1POY) of the same cohort were collected and analyzed in the same manner. Results: About 88.8% of tumor relapse sites were the remnant liver. High SUA levels were associated with male and well-differentiated HCCs. Recurrence-free survival (RFS) of high SUA patients was significantly inferior to low SUA patients [median survival time (MST): 22.7 vs. 28.5 mo, P = 0.033], whereas no difference was observed in overall survival (MST: both not reached, P = 0.771). RFS of high SUA patients at 1POY also showed significantly poorer outcomes than low SUA patients (MST: 29.3 vs. 57.0 mo, P = 0.049). Conclusions: High SUA implies a significant risk factor of activating hepatocarcinogenesis. Keeping the SUA level low may be recommended after HCC resections.